RecruitingPhase 2Biological interventionA Study Evaluating BFB759 in Moderate to Severe Atopic DermatitisThis is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.